Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

>-- Raised $24.8 million in two successful public offerings

Strengthened Intellectual Property Portfolio:

-- Granted a U.S. patent for HPV fusions to treat patients with HPV-

related diseases

-- Granted a U.S. patent covering heat shock protein fusions to treat

anogenital warts

-- Won an important challenge to two U.S. patents; U.S. Patent and

Trademark Office reissued composition of matter and methods of use for

Company's CoVal(TM) fusions

-- Granted European patent covering CoVal(TM) fusion proteins to treat

influenza

Gregory M. McKee, President and Chief Executive Officer at Nventa commented on the year: "2007 was a year of significant events at Nventa. We are very pleased with the progress we made during the past year as we advanced new HspE7 (HspE7 + Poly-ICLC) into a Phase 1 clinical trial and completed the safety evaluation for three of the four cohorts in the trial. We anticipate completing the evaluation of the remaining cohort by the end of the second quarter of 2008, and are working diligently to design the Phase 2 clinical program, expected to begin shortly after this Phase 1 trial, to test new HspE7 in a larger population of patients with cervical dysplasia." Mr. McKee continued, "With the strength of our Directors, the addition of two new senior managers and the creation of a distinguished board of international experts, we look forward to building additional value for our shareholders through the continued advancement of new HspE7 for human papillomavirus (HPV)-related diseases."

Total Year 2007 and Fourth Quarter Financial Results:

All amounts, unless specified otherwise, are in Canadian dollars.

Nventa reported a net loss of $12,413,000, or $0.06 per share, for the year ended December 31, 2007, compared to a net loss of $10,067,000, or $0.12 per share, for the same period in 2006. The increase in net loss in 2007 from 2006 is principally re
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, today announced that ... the United States on the ... September 17, 2014 on the OTCQX under the symbol ... TSX Venture Exchange under its existing symbol SQD. ...
(Date:9/17/2014)... California , 17 de septiembre de ... ("la compañía"), principal proveedor mundial de soluciones ... las ciencias de la vida, anunció hoy ... de logística global con sede en Rótterdam, ... base de clientes Europa en rápido crecimiento. ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF),( http://www.ixsbio.com ... of monoclonal antibodies based on its Dynamic Cross ... a large scale,primate study of DXL625 (CD20), the ... study in cynomolgus monkeys of DXL625, an antibody,directed ...
... Odyssey Thera, Inc. announced,that it has received a ... progress a discovery stage drug candidate into,pre-clinical development. ... as part of the ongoing collaboration with Pfizer., ... of the collaboration with,Pfizer," said John K. Westwick, ...
... (OTC,Pink Sheets: AIMM) today reported a net loss of $86,000, ... ended June 30, 2008, compared with,a net loss of $62,000, ... months ended June 30, 2007. For the six months ended ... share basic and diluted, compared,with net loss of $54,000, or ...
Cached Biology Technology:InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
(Date:9/17/2014)... UT Arlington engineering professor and his doctoral student have ... can accumulate water collected from fog and dew., The ... world or deserts around the globe., Cheng Luo, professor ... Heng, PhD candidate in the same College of Engineering ... 25 edition of ACS, (American Chemical Society) ...
(Date:9/17/2014)... has developed, very cleverly, some lessons on how to ... said Joseph Shaw, director of the Optical Technology Center ... structures at the nanoscale, we,ll discover them." , Some ... August during a conference called "The Nature of Light: ... of the University of Arizona College of Optical Sciences. ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3
... may not be the answer to mitigating climate change by ... to an international team of plant biologists. The researchers found ... fungi (AMF) -- a type of fungus that is often ... then leads to higher decomposition rates of organic materials, said ...
... the methane on Earth comes from the ocean,s oxygen-rich waters, ... this potent greenhouse gas. Now researchers report that they have ... the most abundant microbes on the planet. The findings ... who made the discovery did not set out to explain ...
... part of the marine ecosystem, fostering biodiversity and protecting ... with pollution and harmful fishing practices, are one of ... One of the solutions to the crisis ... Tel Aviv University,s Department of Molecular Microbiology and Biotechnology, ...
Cached Biology News:Plants' fungi allies may not help store climate change's extra carbon 2Study identifies prime source of ocean methane 2Study identifies prime source of ocean methane 3Viruses could be the key to healthy corals 2
... a simple high performance method for removing ... without significant dilution of protein solution. ... Detergent-OUT Spin column and collect detergent free ... removing detergent from a maximum of 0.2 ...
... Chemicon Detergent-OUT SDS Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... Med columns are suitable for removing ...
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7 microns ... large (3-5 mm in diameter) in comparison ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
Biology Products: